Cirrhosis regression in patients with viral hepatitis B and C a systematic review

Journal of Clinical Gastroenterology

Volumn 48, Issue 9, 2014, Pages e76-e84

  Manne, Vignan ^a   Akhtar, Ehsaan ^a   Saab, Sammy ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

Antiviral therapy; Cirrhosis regression; Viral hepatitis

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA INTERFERON; BILIRUBIN; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; TENOFOVIR; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLASSIFICATION ALGORITHM; COCHRANE LIBRARY; DEMOGRAPHY; ELASTOGRAPHY; FOLLOW UP; HEPATITIS B; HEPATITIS C; HISTOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; THROMBOCYTE; TREATMENT DURATION; VIRUS LOAD; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; FIBROSIS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; PATHOLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FIBROSIS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS;

EID: 84921275950     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000162     Document Type: Review

References (74)

1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371: 838-851
2. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7: 122-128
3. Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006;44:472-477
4. Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 Practice Guidelines by the American Association for the study of liver diseases. Hepatology. 2011;54:328-343
5. Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S, et al. Reversibility of cirrhosis in autoimmune hepatitis. Am J Med. 2004;117:125-129
6. Fiel MI, Wu HS, Iyer K, et al. Rapid reversal of parenteralnutrition-associated cirrhosis following isolated intestinal transplantation. J Gastrointes Surg. 2009;13:1717-1723
7. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl JMed. 1993;328:1828-1835
8. Dong MH, Saab S. Complications of cirrhosis. Dis Mon. 2008;54:445-456
9. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017-1044
10. Malekzadeh R, Poustchi H. Fibroscan for assessing liver fibrosis: an acceptable alternative to liver biopsy. Hepat Mon. 2011;11:157-158
11. Fung J, Lai CL, Chan SC, et al. Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. Am J Gastroenterol. 2010;105:1116-1122
12. Casado JL, Quereda C, Moreno A, et al. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV infection. J Viral Hepat. 2013;20:829-837
13. Myers RP, Pomier-Layraragues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199-208
14. Block TM, Gish R, Guo H, et al. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res. 2013;98:27-34
15. Ng V, Saab S. Effects of a sustained virological response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:923-930
16. Manns MP, Pockros PJ, Norkrans G, et al. Sustained virologic response to interferon alfa-2b or peginterferon alfa-2b, alone or in combination with ribavirin predicts long-term clearance of hepatitis C virus. J Viral Hepatol. 2013;20:524-529
17. Swain MG, Lai MY, Shiffman ML, et al. Durable sustained virological response after treatment with peginterferon alpha-2a (PEGASYS (R)) alone or in combination with ribavirin (COPEGUS (R)): 5-year follow-up and the criteria of a cure. J Hepatol. 2007;46:S1-S3
18. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47:598-607
19. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705-1713
20. Du X, Wang J, Shao L, et al. Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels. J Viral Hepatol. 2013;20:328-335
21. Schiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008;103: 2776-2783
22. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468-475
23. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105-117
24. Andersen ES, Weiland O, Leutscher P, et al. Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. Scand J Gastroenterol. 2011;46:760-766
25. Enomoto M, Mori M, Ogawa T, et al. Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: regression of liver stiffness during entecavir therapy. Hepatol Res. 2010;40:853-861
26. Osakabe K, Ichino N, Nishikawa T, et al. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol. 2011;46:1324-1334
27. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122: 1303-1313
28. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517-524
29. Abergel A, Darcha C, Chevallier M, et al. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol. 2004;16:1219-1227
30. D'Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56:532-543
31. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135:821-829
32. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149: 399-403
33. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol. 2004;35:107-112
34. Arif A, Levine RA, Sanderson SO, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci. 2003;48:1425-1430
35. George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729-738
36. Bruno S, Battezzati PM, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 2001;34:748-755
37. Andersen ES, Moessner BK, Christensen PB, et al. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2011;23:41-44
38. Arima YL, Kawabe N, Hashimoto S, et al. Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. Hepatol Res. 2010;40:383-392
39. Calvaruso VL, Di Marco V, Ferraro D, et al. Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. Hepat Mon. 2013;13:e7176
40. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut. 2006;55:403-408
41. Friedrich-Rust M, Ong M-F, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis:A metaanalysis. Gastroenterology. 2008;134:960-974
42. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-893
43. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9:274-276
44. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipoxivil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743-1751
45. Pockros PJ, Hamzeh FM, Martin P, et al. Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology. 2010;52:1193-1200
46. Cammà C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology. 2004;39:333-342
47. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531
48. Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280-288
49. Chen CJ, Yang HI, Su J, et al. Risk of Hepatocellular carcinoma across a biologic gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73
50. Fung J, Lai CL, Yuen MF. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect. 2009;15:964-970
51. Fung J, Lai CL, Seto WK, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011;66:2715-2725
52. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816
53. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-2455
54. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8:350-355
55. Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230-236
56. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicenter cohort of the French early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol. 2013;59:434-441
57. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593
58. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310:804-811
59. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-1887
60. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-1877
61. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39:239-244
62. Fanning L, Loane J, Kenny-Walsh E, et al. Tissue viral load variability in chronic hepatitis C. Am J Gastroenterol. 2001;96:3384-3389
63. Siddique I, El-Naga HA, Madda JP, et al. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol. 2003;38:427-432
64. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-2618
65. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005;41:257-264
66. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142: 1293-1302
67. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007;56:968-973
68. Boursier J, Konate A, Gorea G, et al. Reproducibility of liver stiffness measurement by ultrasonographic elastometry. Clin Gastroenterol Hepatol. 2008;6:1263-1269
69. Myers RP, Elkashab M, Ma M, et al. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol. 2010;24:661-670
70. Fraquelli M, Rigamonti C, Casazza G, et al. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol. 2011;54:621-628
71. Sagir A, Erhardt A, Schmitt M, et al. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology. 2008;47:592-595
72. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol. 2010;44:214-219
73. Gara N, Zhao X, Kleiner DE, et al. Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histology assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;11:303-308
74. D'Ambrosio R, Aghemo A, Fraquelli M, et al. The diagnostic accuracy of FibroScan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virologic response. J Hepatol. 2013;59:251-256.